CHEK1 and lymphoma: When taken together with work from Hunter et al. demonstrating Claspin loss in Eμ-Myc RelA 505A lymphomas, this suggests that these cells are not only more likely to become malignant, but would also be resistant to Chk1 inhibitor treatment, further challenging treatment of these cancers.